Indications: LYBALVI® is indicated for the treatment of adults with schizophrenia or bipolar I disorder for acute treatment of manic or mixed episodes as monotherapy and as an adjunct to lithium or valproate, or as a maintenance monotherapy treatment.

Bipolar I Disorder and Schizophrenia

Efficacy & Safety

Man and woman walking in a park together
Actor portrayals.

Efficacy and safety data

Explore olanzapine efficacy and safety data that provided the basis for the bipolar I disorder indication for LYBALVI.1

See the Data

ENLIGHTEN-1 efficacy and safety data

Explore pivotal trial data demonstrating the efficacy and safety of LYBALVI in schizophrenia.1,2

See the Data

ENLIGHTEN-2 efficacy and safety data

Explore pivotal trial data evaluating the safety of LYBALVI and changes in body weight relative to olanzapine.1,3

See the Data

Get the latest updates about lybalvi

Sign up to receive information and other important updates about LYBALVI.
Sign Up Now
References: 1. LYBALVI [prescribing information]. Alkermes, Inc.; 2021. 2. Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 Study. J Clin Psychiatry. 2020;81(2):e1-e9. 3. Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168-1178.